Notably, resistance to therapeutics is relatively common in oncology, owing to the enhanced proliferative rate of malignant cells, selection pressure caused by therapeutics and resultant selective advantage for resistance mutations.3,6,43 This may not be the case in the use of BTK inhibitors for non-malignant autoimmune conditions such as MS. The gene discussed is BTK; the disease is myeloid sarcoma.